Clinical Trial Update: Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating switching virologically suppressed HIV-1 adults from EFV/FTC/TDF to FTC/RPV/TAF; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• EFV/FTC/TDF (efavirenz/emtricitabine/tenofovir disoproxil fumarate)
• FTC/RPV/TAF (emtricitabine/rilpivirine/tenofovir alafenamide)

Snippet

Sponsor: Gilead Sciences | Conditions: HIV-1 Infection | Phase 3 | Status: COMPLETED | Results posted: 2017-10-19